MADRIGAL PHARMACEUTICALS, INC. Payments to Acquire Available-for-sale Securities
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Payments to Acquire Available-for-sale Securities of $122.19 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-05-08
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $122.19M, a 452.43% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $35.30M, a 358.34% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $3.80M.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $8.99M, a 72.05% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2017 was $70.21M, a 556.36% increase from fiscal 2016.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2016 was $10.70M, a 90.87% decline from fiscal 2015.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2015 was $117.14M, a 24.82% increase from fiscal 2014.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2014 was $93.84M, a 17.79% decline from fiscal 2013.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 9 month as first filed | Payments to Acquire Available-for-sale Securities 12 month | Payments to Acquire Available-for-sale Securities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2018-03-31 | $122.19M 10-Q · filed 2018-05-08 | $157.49M derived: sum of 2 quarters · filed 2018-05-08 | $161.29M derived: sum of 3 quarters · filed 2018-05-08 | $170.28M derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2017-12-31 | $35.30M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $39.10M derived: sum of 2 quarters · filed 2018-03-13 | $48.09M derived: sum of 3 quarters · filed 2018-03-13 | $70.21M 10-K · filed 2018-03-13 | ||
| 2017-09-30 | $3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $12.79M derived: sum of 2 quarters · filed 2017-11-09 | $34.91M 10-Q · filed 2017-11-09 | $42.61M derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2017-06-30 | $8.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $31.11M 10-Q · filed 2017-08-10 | $38.81M derived: sum of 3 quarters · filed 2018-05-08 | $411.00K derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2017-03-31 | $22.12M 10-Q · filed 2018-05-08 | $29.82M derived: sum of 2 quarters · filed 2018-05-08 | -$8.58M derived: sum of 3 quarters · filed 2018-05-08 | $23.60M derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2016-12-31 | $7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$30.70M derived: sum of 2 quarters · filed 2018-03-13 | $1.48M derived: sum of 3 quarters · filed 2018-03-13 | $10.70M 10-K · filed 2018-03-13 | $10.70M 10-K · filed 2017-03-31 | |
| 2016-09-30 | -$38.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$6.22M derived: sum of 2 quarters · filed 2017-11-09 | $3.00M 10-Q · filed 2017-11-09 | $2.99M 10-Q · filed 2016-11-14 | $27.65M derived: sum of 4 quarters · filed 2017-11-09 | |
| 2016-06-30 | $32.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-20 | $41.40M 10-Q · filed 2016-07-20 | $66.06M derived: sum of 3 quarters · filed 2016-07-20 | $79.61M derived: sum of 4 quarters · filed 2016-07-20 | ||
| 2016-03-31 | $9.22M 10-Q · filed 2016-05-10 | $33.88M derived: sum of 2 quarters · filed 2016-05-10 | $47.43M derived: sum of 3 quarters · filed 2016-05-10 | $97.67M derived: sum of 4 quarters · filed 2016-07-20 | ||
| 2015-12-31 | $24.66M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $38.21M derived: sum of 2 quarters · filed 2016-03-15 | $88.45M derived: sum of 3 quarters · filed 2016-07-20 | $117.14M 10-K · filed 2016-03-15 | ||
| 2015-09-30 | $13.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $63.79M derived: sum of 2 quarters · filed 2016-07-20 | $92.48M 10-Q · filed 2015-11-05 | $117.81M derived: sum of 4 quarters · filed 2016-07-20 | ||
| 2015-06-30 | $50.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-20 | $78.92M 10-Q · filed 2016-07-20 | $104.26M derived: sum of 3 quarters · filed 2016-07-20 | $155.05M derived: sum of 4 quarters · filed 2016-07-20 | ||
| 2015-03-31 | $28.68M 10-Q · filed 2016-05-10 | $54.02M derived: sum of 2 quarters · filed 2016-05-10 | $104.81M derived: sum of 3 quarters · filed 2016-05-10 | $118.98M derived: sum of 4 quarters · filed 2016-05-10 | ||
| 2014-12-31 | $25.34M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $76.13M derived: sum of 2 quarters · filed 2016-03-15 | $90.30M derived: sum of 3 quarters · filed 2016-03-15 | $93.84M 10-K · filed 2016-03-15 | ||
| 2014-09-30 | $50.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $64.96M derived: sum of 2 quarters · filed 2015-11-05 | $68.51M 10-Q · filed 2015-11-05 | $111.48M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-06-30 | $14.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $17.71M 10-Q · filed 2015-08-06 | $60.68M derived: sum of 3 quarters · filed 2016-03-15 | $70.58M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-03-31 | $3.55M 10-Q · filed 2015-05-07 | $46.52M derived: sum of 2 quarters · filed 2016-03-15 | $56.41M derived: sum of 3 quarters · filed 2016-03-15 | $62.41M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2013-12-31 | $42.97M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $52.87M derived: sum of 2 quarters · filed 2016-03-15 | $58.86M derived: sum of 3 quarters · filed 2016-03-15 | $114.15M 10-K · filed 2016-03-15 | ||
| 2013-09-30 | $9.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $15.89M derived: sum of 2 quarters · filed 2014-11-06 | $71.18M 10-Q · filed 2014-11-06 | $75.33M derived: sum of 4 quarters · filed 2015-03-12 | ||
| 2013-06-30 | $5.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | $61.28M 10-Q · filed 2014-08-06 | $65.43M derived: sum of 3 quarters · filed 2015-03-12 | $88.56M derived: sum of 4 quarters · filed 2015-03-12 | ||
| 2013-03-31 | $55.29M 10-Q · filed 2014-05-08 | $59.44M derived: sum of 2 quarters · filed 2015-03-12 | $82.57M derived: sum of 3 quarters · filed 2015-03-12 | $82.50M derived: sum of 4 quarters · filed 2015-03-12 | ||
| 2012-12-31 | $4.15M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $27.28M derived: sum of 2 quarters · filed 2015-03-12 | $27.21M derived: sum of 3 quarters · filed 2015-03-12 | $50.03M 10-K · filed 2015-03-12 | ||
| 2012-09-30 | $23.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-04 | $23.06M derived: sum of 2 quarters · filed 2013-11-04 | $45.89M 10-Q · filed 2013-11-04 | $49.62M derived: sum of 4 quarters · filed 2014-03-11 | ||
| 2012-06-30 | -$67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $22.76M 10-Q · filed 2013-08-01 | $26.49M derived: sum of 3 quarters · filed 2014-03-11 | $33.82M derived: sum of 4 quarters · filed 2014-03-11 | ||
| 2012-03-31 | $22.82M 10-Q · filed 2013-04-30 | $26.56M derived: sum of 2 quarters · filed 2014-03-11 | $33.89M derived: sum of 3 quarters · filed 2014-03-11 | $59.02M derived: sum of 4 quarters · filed 2014-03-11 | ||
| 2011-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-11 | $11.06M derived: sum of 2 quarters · filed 2014-03-11 | $36.19M derived: sum of 3 quarters · filed 2014-03-11 | $50.73M 10-K · filed 2014-03-11 | ||
| 2011-09-30 | $7.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $32.46M derived: sum of 2 quarters · filed 2012-11-06 | $46.99M 10-Q · filed 2012-11-06 | $64.70M derived: sum of 4 quarters · filed 2013-03-14 | ||
| 2011-06-30 | $25.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $39.66M 10-Q · filed 2012-08-02 | $57.37M derived: sum of 3 quarters · filed 2013-03-14 | $70.53M derived: sum of 4 quarters · filed 2013-03-14 | ||
| 2011-03-31 | $14.53M 10-Q · filed 2012-05-03 | $32.24M derived: sum of 2 quarters · filed 2013-03-14 | $45.40M derived: sum of 3 quarters · filed 2013-03-14 | |||
| 2010-12-31 | $17.70M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-14 | $30.87M derived: sum of 2 quarters · filed 2013-03-14 | $36.92M 10-K · filed 2013-03-14 | |||
| 2010-09-30 | $13.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $19.21M 10-Q · filed 2011-11-03 | ||||
| 2010-06-30 | $6.05M 10-Q · filed 2011-08-04 | |||||
| 2009-12-31 | $39.30M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |